Evidence map›Paper›PMID 26303700›Full record

Trial reportJournal of geriatric psychiatry and neurology2016

Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.

Matthew E Peters, Vijay Vaidya, Lea T Drye, Davangere P Devanand, Jacobo E Mintzer, Bruce G Pollock, Anton P Porsteinsson, Paul B Rosenberg, Lon S Schneider, David M Shade and 5 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of geriatric psychiatry and neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Alzheimer's Disease: Cellular and Pharmacological Aspects.Geriatrics (Basel, Switzerland) · 2024
    Review
  2. Article
  3. Psychosis in Alzheimer's Disease.Current neurology and neuroscience reports · 2020
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 2 countries.

Matthew E PetersJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Vijay VaidyaJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Lea T DryeJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Davangere P DevanandColumbia University Medical Center, New York, NY, USA.
Jacobo E MintzerMedical University of South Carolina, Charleston, SC, USA.
Bruce G PollockCentre for Addiction and Mental Health, Campbell Family Institute, Toronto, Canada University of Toronto, Toronto, Canada.
Anton P PorsteinssonUniversity of Rochester School of Medicine, Rochester, NY, USA.
Paul B RosenbergJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Lon S SchneiderKeck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
David M ShadeJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Daniel WeintraubUniversity of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Jerome YesavageStanford University School of Medicine, Stanford, CA, USA.
Constantine G LyketsosJohns Hopkins University School of Medicine, Baltimore, MD, USA kostas@jhmi.edu.
Dimitri AvramopoulosJohns Hopkins University School of Medicine, Baltimore, MD, USA.
CitAD Research Group
Johns Hopkins University · USJohns Hopkins Medicine · USCentre for Addiction and Mental Health · CAColumbia University Irving Medical Center · USMedical University of South Carolina · USStanford University · USUniversity of Pennsylvania · USUniversity of Rochester · USUniversity of Southern California · US

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARANDA, MARIA P. · 1985 to 2019
$41.0M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
Citalopram Treatment for Agitation in Alzheimer DementiaR01AG031348 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 2008 to 2012
$7.9M
Research Training in Age-Related Cognitive DisordersT32AG027668 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2007 to 2026
$6.3M
NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG031348NIA NIH HHS R01AG031348NIA NIH HHS T32 AG027668
6 · The paper itself

Abstract

objectiveTo assess potential genetic influences on citalopram treatment efficacy for agitation in individuals with Alzheimer dementia (AD). Six functional genetic variants were studied in the following genes: serotonin receptor 2A (HTR2A-T102C), serotonin receptor 2C (HTR2C-Cys23Ser), serotonin transporter (5HTT-LPR), brain-derived neurotropic factor (BDNF-Val66Met), apolipoprotein E (ε2, ε3, ε4 variants), and cytochrome P450 (CYP2C19). Treatment response by genotype was measured by (1) the agitation domain of the Neurobehavioral Rating Scale, (2) the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change scale (mADCS-CGIC), (3) the agitation domain of the Neuropsychiatric Inventory (NPI), and (4) the Cohen-Mansfield Agitation Inventory.

methodWe utilized data from the Citalopram for Agitation in Alzheimer's Disease (CitAD) database. CitAD was a 9-week randomized, double-blind, placebo-controlled multicenter clinical trial showing significant improvement in agitation and caregiver distress in patients treated with citalopram. Proportional odds logistic regression and mixed effects models were used to examine the above-mentioned outcome measures.

resultsSignificant interactions were noted on the NPI agitation domain for HTR2A (likelihood ratio [LR] = 6.19, df = 2, P = .04) and the mADCS-CGIC for HTR2C (LR = 4.33, df = 2, P = .02) over 9 weeks. DISCUSSION: Treatment outcomes in CitAD showed modest, although statistically significant, influence of genetic variation at HTR2A and HTR2C loci. Future studies should continue to examine the interaction of known genetic variants with antidepressant treatment in patients with AD having agitation.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAntidepressive AgentsApolipoproteins EBrain-Derived Neurotrophic FactorCaregiversCitalopramCytochrome P-450 CYP2C19Databases, FactualDouble-Blind MethodFemaleGenotypeHumansMalePsychomotor AgitationAntidepressive AgentsApolipoproteins EBDNF protein, humanBrain-Derived Neurotrophic FactorCitalopramCYP2C19 protein, humanCytochrome P-450 CYP2C19Receptors, SerotoninSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport ProteinsagitationAlzheimer diseaseantidepressantcitalopramdementiageneticsrandomized trial

Identifiers

PMID26303700
PMCPMC5166612
OpenAlexW2169346955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.